Sectors & IndustriesHealthcareDrug Manufacturers - Specialty & Generic

Best Pharmaceutical Stocks to Buy Now (2024)

Top pharmaceutical stocks in 2024 ranked by overall Zen Score. See the best pharmaceutical stocks to buy now, according to analyst forecasts for the drug manufacturers - specialty & generic industry.

According to Zen Score, the 3 best pharma stocks to buy right now are:

Amphastar Pharmaceuticals (NASDAQ:AMPH) is the top pharmaceutical stock with a Zen Score of 69, which is 43 points higher than the pharmaceutical industry average of 26. It passed 23 out of 33 due diligence checks and has strong fundamentals. Amphastar Pharmaceuticals has seen its stock return 3.23% over the past year, overperforming other pharmaceutical stocks by 33 percentage points.

Amphastar Pharmaceuticals has an average 1 year price target of $66.00, an upside of 42.49% from Amphastar Pharmaceuticals's current stock price of $46.32.

Amphastar Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Amphastar Pharmaceuticals, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Neurocrine Biosciences (NASDAQ:NBIX) is the second best pharmaceutical stock with a Zen Score of 68, which is 42 points higher than the pharmaceutical industry average of 26. It passed 23 out of 33 due diligence checks and has strong fundamentals. Neurocrine Biosciences has seen its stock return 1.24% over the past year, overperforming other pharmaceutical stocks by 31 percentage points.

Neurocrine Biosciences has an average 1 year price target of $169.94, an upside of 51.9% from Neurocrine Biosciences's current stock price of $111.88.

Neurocrine Biosciences stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 18 analysts covering Neurocrine Biosciences, 55.56% have issued a Strong Buy rating, 27.78% have issued a Buy, 16.67% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Collegium Pharmaceutical (NASDAQ:COLL) is the third best pharmaceutical stock with a Zen Score of 60, which is 34 points higher than the pharmaceutical industry average of 26. It passed 19 out of 33 due diligence checks and has strong fundamentals. Collegium Pharmaceutical has seen its stock return 75.19% over the past year, overperforming other pharmaceutical stocks by 105 percentage points.

Collegium Pharmaceutical has an average 1 year price target of $42.60, an upside of 6.79% from Collegium Pharmaceutical's current stock price of $39.89.

Collegium Pharmaceutical stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Collegium Pharmaceutical, 40% have issued a Strong Buy rating, 40% have issued a Buy, 20% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 7 pharmaceutical stocks that have issued dividends in the past year, the 3 pharmaceutical stocks with the highest dividend yields are:

Guardion Health Sciences (NASDAQ:GHSI) has an annual dividend yield of 142.86%, which is 122 percentage points higher than the pharmaceutical industry average of 20.42%.

Guardion Health Sciences's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 8.62%, which is -12 percentage points lower than the pharmaceutical industry average of 20.42%.

Siga Technologies's dividend payout ratio of 51.3% indicates that its high dividend yield is sustainable for the long-term.

Alkermes (NASDAQ:ALKS) has an annual dividend yield of 3.77%, which is -17 percentage points lower than the pharmaceutical industry average of 20.42%.

Alkermes's dividend payout ratio of 61.8% indicates that its dividend yield is sustainable for the long-term.

Pharmaceutical stocks were down -0.05% in the last day, and up 0.04% over the last week.

We couldn't find a catalyst for why pharmaceutical stocks are down.

Based on WallStreetZen's Valuation Score, the 3 most undervalued pharmaceutical stocks right now are:

Collegium Pharmaceutical (NASDAQ:COLL) is the most undervalued pharmaceutical stock based on WallStreetZen's Valuation Score. Collegium Pharmaceutical has a valuation score of 86, which is 72 points higher than the pharmaceutical industry average of 14. It passed 6 out of 7 valuation due diligence checks.

Collegium Pharmaceutical's stock has gained 75.19% in the past year. It has overperformed other stocks in the pharmaceutical industry by 105 percentage points.

Kamada (NASDAQ:KMDA) is the second most undervalued pharmaceutical stock based on WallStreetZen's Valuation Score. Kamada has a valuation score of 71, which is 57 points higher than the pharmaceutical industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Kamada's stock has dropped -2.45% in the past year. It has overperformed other stocks in the pharmaceutical industry by 27 percentage points.

Amphastar Pharmaceuticals (NASDAQ:AMPH) is the third most undervalued pharmaceutical stock based on WallStreetZen's Valuation Score. Amphastar Pharmaceuticals has a valuation score of 71, which is 57 points higher than the pharmaceutical industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Amphastar Pharmaceuticals's stock has gained 3.23% in the past year. It has overperformed other stocks in the pharmaceutical industry by 33 percentage points.